Rising Pharma Holdings, Inc. of East Brunswick, New Jersey, is recalling 11,460 bottles of Chlorthalidone Tablets USP 25mg after the tablets failed dissolution specifications during quality control testing — meaning they may not dissolve properly in the body and could be less effective or ineffective at controlling blood pressure. The recall was initiated June 5, 2026, by manufacturer Inventia Healthcare Limited, and classified Class II by the FDA on June 22, 2026. No adverse events have been reported. This is the second recall of a commonly prescribed blood pressure medication in under a year.
What’s Being Recalled?
The recall covers Chlorthalidone Tablets USP, 25 mg, in two bottle sizes:
100-tablet bottles — batch number RISA24001, expiration date April 2027.
1,000-tablet bottles — batch number RISB24002, expiration date April 2027.
The batch number and expiration date are printed on the bottle label. The tablets were manufactured by Inventia Healthcare Limited in India and distributed nationwide by Rising Pharma Holdings, Inc. Chlorthalidone is a prescription diuretic used to treat high blood pressure and fluid retention from heart, kidney, or liver disease. The Class II classification indicates serious adverse consequences are remote, but temporary or reversible effects are possible.
Why Was This Product Recalled?
The recalled tablets failed dissolution specifications, meaning quality control testing found they do not dissolve in the body at the rate and completeness required. When a tablet fails dissolution standards, the full prescribed dose may not be absorbed — a serious concern for a drug managing a chronic condition. For patients with high blood pressure, an ineffective dose could mean blood pressure is not adequately controlled, increasing the risk of stroke, heart attack, and kidney damage over time.
What Should You Do?
Check the label of your chlorthalidone 25mg bottle for batch number RISA24001 (100-tablet bottles) or RISB24002 (1,000-tablet bottles) with an expiration date of April 2027. If your bottle matches, contact your prescribing doctor or pharmacist immediately. Do not stop taking chlorthalidone without medical guidance — abruptly discontinuing blood pressure medication can cause a rebound spike in blood pressure that may be more immediately dangerous than continuing the recalled tablets. Your pharmacist can confirm whether your specific bottle is affected and arrange a replacement from an unaffected lot. You may also return the recalled product to the place of purchase for a refund. Report adverse events to the FDA’s MedWatch program at fda.gov/safety/medwatch or call 1-800-332-1088.
